List of life sciences

Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022

Retrieved on: 
Thursday, October 27, 2022

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, announced today it will report financial results for the third quarter of 2022 after market close on Thursday, November 10, 2022.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, announced today it will report financial results for the third quarter of 2022 after market close on Thursday, November 10, 2022.
  • Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers.
  • Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Trinity Life Sciences Launches Quick Payer Pulse, Allowing Clients to Validate Pricing and Access Assumptions in Days

Retrieved on: 
Thursday, October 27, 2022

Trinity Life Sciences , a leader in global life sciences commercialization solutions, introduces Quick Payer Pulsea proprietary survey tool that generates and quantifies country-specific payer insights to support time-sensitive business needs.

Key Points: 
  • Trinity Life Sciences , a leader in global life sciences commercialization solutions, introduces Quick Payer Pulsea proprietary survey tool that generates and quantifies country-specific payer insights to support time-sensitive business needs.
  • In life sciences, pricing and access are vital to an assets success globally.
  • Quick Payer Pulse enables rapid, informed business decisions by leveraging Trinitys in-depth knowledge of the global payer landscapeand access to payer stakeholdersto provide a snapshot of payer perceptions within days.
  • Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences.

Snowflake Achieves New HITRUST Risk-based, 2-Year Certification to Manage Risk, Improve Security Posture, and Meet Compliance Requirements

Retrieved on: 
Thursday, October 27, 2022

Snowflake , the Data Cloud company, today announced that it has achieved HITRUST r2 Certification for information security.

Key Points: 
  • Snowflake , the Data Cloud company, today announced that it has achieved HITRUST r2 Certification for information security.
  • This achievement places Snowflake in an elite group of organizations worldwide that have earned this certification.
  • In addition, HITRUST is a certifiable and recommended framework trusted by many health networks and hospitals to manage risk.
  • Snowflakes HITRUST Risk-based 2-year Certification is evidence that they are at the forefront of industry best practices for information risk management and compliance.

Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program

Retrieved on: 
Thursday, October 27, 2022

The studies are part of the Companys ongoing collaboration with the National Cancer Institute (NCI) to link DecisionDx-Melanoma and DecisionDx-UM clinical testing data with data from the Surveillance, Epidemiology and End Results (SEER) Programs registries on CM and UM cases, respectively.

Key Points: 
  • The studies are part of the Companys ongoing collaboration with the National Cancer Institute (NCI) to link DecisionDx-Melanoma and DecisionDx-UM clinical testing data with data from the Surveillance, Epidemiology and End Results (SEER) Programs registries on CM and UM cases, respectively.
  • The data were shared in poster presentations at the 19th International Congress of the Society for Melanoma Research (SMR) in Edinburgh, United Kingdom.
  • In the study, DecisionDx-Melanoma was a statistically significant and independent predictor of melanoma-specific survival (MSS), consistent with previously published retrospective and prospective studies.
  • Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make.

Caron Products Names Tom Kroeger Global Director of Quality

Retrieved on: 
Thursday, October 27, 2022

MARIETTA, Ohio, Oct. 27, 2022 /PRNewswire/ -- Caron Products and Services, Inc. ("Caron"), a leading provider of laboratory equipment used in small and large molecule drug development and manufacturing, cell and gene therapy research, and academic research, today announced Tom Kroeger has joined Caron's Leadership Team as Global Director of Quality. Based in Northwest Ohio and reporting directly to the CEO, he will focus on advancing the organizations development of quality strategies with an emphasis on Global Quality Systems supporting Caron's continued growth across North America, Europe, and Asia.

Key Points: 
  • MARIETTA, Ohio, Oct. 27, 2022 /PRNewswire/ -- Caron Products and Services, Inc. ("Caron"),a leading provider of laboratory equipment used in small and large molecule drug development and manufacturing, cell and gene therapy research, and academic research, today announced Tom Kroeger has joined Caron's Leadership Team as Global Director of Quality.
  • Tom brings extensive knowledge in quality systems design and implementation, specifically related to plasmapheresis and aseptic processing.
  • "I am excited to welcome Tom to the Caron organization.His strong background in quality assurance systemsand federal regulations will better position Caron to meet the ever-changing demands of both current and emerging markets," said Jay Hexamer, Caron President and CEO.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/caron-products-names-tom-kroege...
    SOURCE Caron Products and Services, Inc. ("Caron")

Spruce Biosciences to Participate in November Investor Conferences

Retrieved on: 
Wednesday, October 26, 2022

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in November.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in November.
  • Interested parties can access the webcast for conference presentations from the events section of the companys investor relations website .
  • Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need.
  • Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess.

Data Silicon Awards: Kalray Wins Gold Innovation Award, Public Award and Bronze Grand Prize With Its New Generation DPU Processor

Retrieved on: 
Wednesday, October 26, 2022

Organized as part of the Silicon Day Data, the Silicon Data Awards recognize the best data projects, solutions and innovations in the IT and tech world.

Key Points: 
  • Organized as part of the Silicon Day Data, the Silicon Data Awards recognize the best data projects, solutions and innovations in the IT and tech world.
  • These awards once again recognize Kalrays unique technology, which also won an award at the Flash Memory Summit last August.
  • With its patented 80-core architecture, Kalray's DPU processor manages multiple data streams in parallel and without bottlenecks.
  • Kalrays DPU is a low-power, high-performance programmable processor dedicated to data-intensive applications for fast-growing markets such as the data center, AI, edge computing, 5G, automotive ...

Dassault Systèmes Partners with Sanofi to Optimize Tech Transfer and Industrialization at Its Future “EVolutive Facilities”

Retrieved on: 
Wednesday, October 26, 2022

Dassault Systmes (Euronext Paris: FR0014003TT8, DSY.PA) and Sanofi today announced their partnership to optimize EVolutive Facility production at Sanofis future state-of-the-art modular manufacturing facilities in France and Singapore.

Key Points: 
  • Dassault Systmes (Euronext Paris: FR0014003TT8, DSY.PA) and Sanofi today announced their partnership to optimize EVolutive Facility production at Sanofis future state-of-the-art modular manufacturing facilities in France and Singapore.
  • Sanofi will use Dassault Systmes Made to Cure for BioPharma industry solution experience based on the 3DEXPERIENCE platform to design, implement, qualify and operate modular production lines at the two EVolutive Facilities.
  • Sanofi can experience the manufacturing systems under development and their operation virtually and optimize scale up and industrialization processes before deploying them.
  • Dassault Systmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries.

Enveda Biosciences appoints industry leader Mark Deeg, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Tuesday, October 25, 2022

Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the companys Chief Medical Officer.

Key Points: 
  • Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the companys Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20221025006040/en/
    Enveda Biosciences today announced the appointment of industry leader Mark Deeg, M.D., Ph.D., as the company's Chief Medical Officer.
  • (Photo: Business Wire)
    We are thrilled to welcome Mark Deeg to Enveda as our Chief Medical Officer, said Viswa Colluru, Ph.D., founder and CEO of Enveda.
  • Prior to this tenure at Cullgen, Mark held positions in medical and research leadership in companies focused on digital and mRNA therapies.

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on: 
Tuesday, October 25, 2022

The equity awards were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.

Key Points: 
  • The equity awards were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.
  • Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer.
  • In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer.
  • For more information about Arcus Biosciences clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.